RESUMEN
OBJECTIVE: To summarize formulary-relevant issues for follow-on insulins approved through the Food and Drug Administration (FDA) 505(b)(2) approval pathway (Basaglar and Admelog). DATA SOURCES: A search of the MEDLINE database was performed for articles pertaining to clinical and formulary considerations for follow-on insulin products through July 2018. STUDY SELECTION AND DATA EXTRACTION: All clinical trials used in the 505(b)(2) approval process for follow-on insulin glargine and insulin lispro products were included and summarized. DATA SYNTHESIS: Follow-on insulin glargine and insulin lispro products have been recently approved as the first lower-cost alternatives to innovator insulin products. The follow-on insulins were approved via the 505(b)(2) pathway, making them neither generics nor biosimilars. Current data do not suggest any clinically relevant differences between the follow-on insulins and their respective innovator products. Clinicians should be aware that follow-on insulins will be reclassified as biologic products in the year 2020. Relevance to Patient Care and Clinical Practice: This article provides information about currently available follow-on insulin products that were approved through the 505(b)(2) pathway, including product characteristics and efficacy and safety data. These products will likely be considered for both clinical use and formulary placement because of their potentially lower cost compared with innovator products. CONCLUSIONS: Follow-on insulin products approved through the 505(b)(2) pathway are supported by robust efficacy and safety data. As new follow-on insulins are approved and the regulatory change that will occur with these products in 2020 approaches, formulary decisions and clinical policies (eg, substitution) will continue to be revisited.
Asunto(s)
Biosimilares Farmacéuticos/síntesis química , Biosimilares Farmacéuticos/uso terapéutico , Aprobación de Drogas , Composición de Medicamentos , Insulinas , Biosimilares Farmacéuticos/química , Biosimilares Farmacéuticos/normas , Aprobación de Drogas/legislación & jurisprudencia , Composición de Medicamentos/métodos , Composición de Medicamentos/normas , Medicamentos Genéricos , Humanos , Hipoglucemiantes/uso terapéutico , Insulina/síntesis química , Insulina/química , Insulina/normas , Insulina/uso terapéutico , Insulina Glargina/síntesis química , Insulina Glargina/química , Insulina Glargina/uso terapéutico , Insulinas/síntesis química , Insulinas/química , Insulinas/normas , Insulinas/uso terapéutico , Estados Unidos , United States Food and Drug Administration/legislación & jurisprudencia , United States Food and Drug Administration/normasRESUMEN
Biosimilar insulins are likely to enter clinical practice in Europe in the near future. It is important that clinicians are familiar with and understand the concept of biosimilarity and how a biosimilar drug may differ from its reference product. The present article provides an overview of biosimilars, the European regulatory requirements for biosimilars and safety issues. It also summarizes the current biosimilars approved in Europe and the key clinical issues associated with the use of biosimilar insulins.
Asunto(s)
Biosimilares Farmacéuticos/normas , Insulinas/normas , Biosimilares Farmacéuticos/uso terapéutico , Medicamentos Genéricos/normas , Europa (Continente) , Humanos , Insulinas/uso terapéutico , Legislación de MedicamentosRESUMEN
Insulin analog patent expiry is likely to mean that, increasingly, copies of original biopharmaceutical products will be submitted for authorization. Experience with biosimilars in other therapeutic areas suggests that careful regulation and caution are needed. Published guidelines of regulatory authorities around the world on approval of biosimilars and, where available, insulin biosimilars were reviewed. Information was sourced through Internet searching and cross-referencing guidelines. As of August 2014, general biosimilar and insulin-specific guidelines are available in 34 countries and two countries/regulatory domains, respectively. Many guidelines are clearly related to, or partly derived from, the general and insulin-specific European Medicines Agency (EMA) guidelines. Areas covered by these guidelines are fairly consistent, covering preclinical, pharmacokinetic (PK), and pharmacodynamic (PD) studies in humans and clinical areas; however, there are differences in emphasis. The EMA insulin-specific guidelines include detailed criteria on PK/PD studies, as do most other general biosimilar guidelines and, to a lesser extent, clinical studies. The U.S. Food and Drug Administration has general biosimilar guidelines, emphasizing consideration of the whole package of in vitro, biological, and human studies, rather than concentrating on any one aspect. In countries such as Mexico, guidelines are broad, leaving wide discretion to the regulatory authority. In conclusion, from a global perspective, this area of drug regulation is heterogeneous and evolving, and the authors call for an initiative aimed at harmonizing the requirements for biosimilar insulins.
Asunto(s)
Biosimilares Farmacéuticos/normas , Aprobación de Drogas/legislación & jurisprudencia , Insulinas/normas , Biosimilares Farmacéuticos/uso terapéutico , Aprobación de Drogas/métodos , Europa (Continente) , Humanos , Insulinas/uso terapéutico , México , Estados Unidos , United States Food and Drug AdministrationRESUMEN
Biologic drugs, such as currently prescribed insulins, are large, complex, 3-dimensional molecules manufactured in biological systems. The complexity of the structure of the biologic drug and its manufacturing process means that it is challenging to create a biologic drug that is identical to the original branded drug. With the potential availability on the horizon of follow-on insulin products (also known as biosimilar insulins) in the United States and other countries where they are not currently in use, physicians (and other prescribers) need to be aware of the potential benefits and concerns regarding biosimilar insulins in order to facilitate informed decision making and to provide the best possible advice and guidance to their patients with diabetes. This article offers a brief, practical overview regarding biosimilar insulins by answering 10 key questions about the topic.